drugset / Trial / NCT06612775
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
Timeline
- Start
- 2024-09
- Primary completion
- 2026-08
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB03-154 | Unknown | 5 mg | Oral |
| Subject | CB03-154 | Unknown | 10 mg | Oral |
| Subject | CB03-154 | Unknown | 20 mg | Oral |